Immunomedics Inc.

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. The company's product candidate is sacituzumab govitecan (IMMU-132), an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. The company also has other product candidates, which target solid tumors and hematologic malignancies in various stages of clinical and preclinical development, such as labetuzumab govitecan that binds the CEACAM5 antigen expressed on CRC and other solid cancers, and IMMU-140 for the treatment of hematologic malignancies.
  • TickerIMMU
  • ISINUS4529071080
  • CountryUnited States
Jonathan Moreland

InsiderInsights Weekly Tables: October 3, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

IMMUNOMEDICS reduced its risk exposure resulting in an upgrade to Slightly Positive

IMMUNOMEDICS (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 4 out of 4 possible stars; its market behaviour has improved and can be considered as moderately risky. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date September 18, 2020, the closing price was USD 85.53 and its potential was estimated at USD 89.81.

Jonathan Moreland

InsiderInsights Daily Ratings Report: September 15, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bulls Still In Driver's Seat, But For How Long? Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. · Sector Relative Strength Rankings & Weighting Recommendations. On Monday, all the areas most-negatively affected by COVID-19 (airlines, cruise ships, etc....

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Outlook Intact Amid rising Middle East tensions, investors have moved to safe-havens including Treasuries and gold, all while having a muted effect on the US equity market. At this point in time, the rising tensions have done virtually no damage to the bullish trends and indicators that continue to dominate the market. We remain bullish. • 10-Year Treasury. The 10-year yield has fallen to logical support at the uptrend or 1.75%, a level we expect to hold. A breakdown would raise concerns of a deeper pullback for US equities... see chart below. • Gold Testing Key Resistance. Gold...

Jonathan Moreland

InsiderInsights Weekly Tables: October 3, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: September 15, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upside Momentum Lost, But Not Breaking Down Uptrends from the March lows were violated late last week for the S&P 500, Nasdaq, and Dow. Additionally, the S&P 500 failed to break above the 61.8% Fibonacci retracement level of 2934.49, while the Nasdaq and Dow also stalled at key resistance levels. This tells us that recent highs are likely to represent a near-term top. As we outlined in last week's Compass, our base case was for some near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening; this is where we are right now as the market has los...

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 1, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

IMMUNOMEDICS reduced its risk exposure resulting in an upgrade to Slightly Positive

IMMUNOMEDICS (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 4 out of 4 possible stars; its market behaviour has improved and can be considered as moderately risky. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date September 18, 2020, the closing price was USD 85.53 and its potential was estimated at USD 89.81.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch